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A novel crosstalk between CCAR2 and AKT pathway in
the regulation of cancer cell proliferation
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Human CCAR2 has recently emerged as having a pivotal role in the DNA damage response, promoting apoptosis and repair of
heterochromatic DNA breaks. However, less is known about the function of CCAR2 in tumor formation and cancer progression.
Here, we demonstrate, for the first time, that CCAR2 loss inhibits the proliferation of cancer cells, but preserves the growth of
normal cells. Investigating the mechanisms responsible for this differential effect, we found that CCAR2 depletion specifically
impairs the activation of AKT pathway in cancer cells, but not in normal cells, by reducing AKT phosphorylation on Ser473. This
effect is achieved through the transcriptional upregulation of TRB3 gene and accumulation of TRB3 protein, which then binds to
and inhibits the phosphorylation and activation of AKT. The defective activation of AKT finally results in reduced GSK3β
phosphorylation, prevention of G1/S transition and inhibition of cancer cell growth. These results establish an important role for
CCAR2 in cancer cells proliferation and could shed new light on novel therapeutic strategies against cancer, devoid of detrimental
side effects.
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Human CCAR2 (cell cycle and apoptosis regulator 2, also
known as DBC1) is a nuclear protein involved in various
biological processes including DNA damage response,
metabolism, epigenetics, nuclear receptor function, circadian
cycle, mRNA splicing,1 and B cell development.2 We
previously demonstrated that CCAR2, phosphorylated by
ATM/ATR and cooperating with the checkpoint kinase Chk2
and the proteasome subunit REGγ, negatively regulates the
NAD+-dependent histone deacetylase SIRT1, promoting p53
activation and apoptosis induction in presence of DNA
damage.3,4 Recently, we also reported that CCAR2 itself
modulates the activity of Chk2 towards KRAB-associated
protein 1 (KAP1), thus influencing the repair of DNA breaks.5
However, although the role of CCAR2 in the DNA damage
response is well established, its function in tumor formation
and cancer progression is still controversial. Originally named
DBC1 by mistake because its gene maps to a region of
chromosome 8 that was found homozygously deleted in
breast cancers,1 CCAR2 was instead upregulated in many
types of tumors.1 These findings, together with the fact that
CCAR2 loss in vitro prevents cancer cells growth6,7 suggested
for this protein a role of tumor promoter. On the other hand,
CCAR2-knockout mice are tumor prone8 and, intriguingly, in
some cancer patients, CCAR2 down-regulation is associated
with poor prognosis,1 suggesting that it acts as tumor
suppressor.
The PI3K-AKT pathway has a major role in regulating
cellular processes that are hallmarks of cancer cells, like
proliferation, survival or migration. This signaling cascade is
frequently hyperactivated in human malignancies9,10 thus
representing an attractive target for cancer therapy. Indeed
inhibitors of the PI3K-AKT pathway are being tested in clinical
trials.11 PI3Ks constitute a family of lipid kinases that, in
response to growth factor stimulation, are phosphorylated and
activated by cell surface receptor tyrosine kinases, such as
platelet-derived growth factor receptor, insulin-like growth
factor 1 receptor and epidermal growth factor receptor. Once
activated, PI3Ks catalytic subunit converts the substrate
phosphatidylinositol 4,5-biphosphate into phosphatidylinosi-
tol-3,4,5-triphosphate on the plasma membrane, which in turn
recruits signaling proteins including the phosphoinositide-
dependent kinase-1 and AKT.10 AKT is activated by
phosphorylation at threonine 308 (Thr308) and at serine
473 (Ser473). Once activated, AKT phosphorylates a large
number of downstream targets, which regulate cell growth and
protein synthesis, increasing proliferation and cell cycle
progression.12 AKT activity is negatively regulated by the
phosphatase and tensin homolog PTEN that, by depho-
sphorylating phosphatidylinositol-3,4,5-triphosphate, blocks
AKT recruitment to the cell membrane finally resulting in the
inhibition of AKT signaling pathway.13 Among the inhibitors of
AKTactivation there is also the protein TRB3, a pseudokinase
characterized by a kinase-like domain lacking the conserved
catalytic residues.14 Specifically, TRB3 inhibits AKTactivation
by binding to this kinase and blocking its phosphorylation on
Ser473 by mTORC2.15 Accordingly it was also reported that
administration of different anti-cancer agents promotes cancer
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cell death via TRB3 upregulation and the subsequent
inhibition of AKT.16
Here, we show for the first time that CCAR2, TRB3 and AKT
are linked together in a regulatory pathway that controls
cancer cell proliferation and leaves unaffected the growth of
nonmalignant cells. In particular, we demonstrate that CCAR2
loss causes a strong reduction of cancer cell proliferation
associated with a significant increase of TRB3 at both
transcript and protein level. Finally, augmented TRB3 pro-
motes the inhibition of AKTactivation and G1/S transition.
Results
CCAR2 depletion impairs U2OS cell proliferation by
altering the AKT pathway. To evaluate the effect of CCAR2
depletion on cellular proliferation, U2OS cells were trans-
fected with a pool of four different CCAR2 iBONi siRNAs
(RIBOXX), which provide an effective silencing for up to
10 days (Figure 1a), and the growth ability and colony forming
efficiency was evaluated at different time points. Depletion of
CCAR2 induced a significant decrease in U2OS cell
proliferation and colony formation (Figures 1b and c).
Conversely, a similar analysis performed with a population
of BJ-hTERT-KO cells5 revealed no proliferation defects
(Figure 1d). Collectively these results demonstrate that
CCAR2 loss impairs the growth of U2OS, but not of BJ-
hTERT cells.
To investigate the mechanism underlying the regulation of
U2OS cells growth by CCAR2, we performed a genome-wide
gene expression analysis in control (siLUC) and CCAR2
silenced U2OS cells 6 days after transfection (Supplementary
Figure 1). Microarray analysis identified 165 CCAR2 regulated
genes that exhibited a fold change41.5 between siLUC and
siCCAR2 transfected cells. Overall, 97 of these genes (58.8%)
were found to be upregulated, whereas 68 (41.2%) were
downregulated (Figure 2a; Supplementary Table 1). To gain
insights into the function of CCAR2 regulated genes, we
carried out an ingenuity pathway analysis (IPA) and found that
among the five top molecular and cellular functions, ‘Cellular
growth and proliferation’ and ‘Cell death and survival’ were
included (Supplementary Table 2). In addition, we identified
three networks strongly altered in CCAR2 silenced cells,
compared with controls, named N1, N2 and N3
(Supplementary Figures 2A–C). All these pathways are
involved in sustaining cancer cell growth and N1 has NF-kB
as the hub gene, N2 includes several genes regulating AKT
Figure 1 CCAR2 depletion strongly inhibits U2OS cell proliferation. (a) Western blot (WB) analysis demonstrating CCAR2 depletion for up to 10 days after siRNA
transfection. (b) Cell proliferation rate in control and CCAR2 silenced U2OS cells. **Po0.01. (c) Colony forming assays in U2OS cells silenced for CCAR2 (top). Colonies were
counted and expressed as a percentage of siLUC control. Results are mean +/− S.D. from three inedependent experiments. **Po0.01 (d) Cell proliferation rate (top) and WB
analysis (bottom) of BJ-hTERT control cells and CCAR2-KO mass culture
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kinase and N3 is linked to ERK1/2 pathway. A similar analysis
was also performed between parental BJ-hTERT and the
mass culture of BJ-hTERT-KO for CCAR2 gene, that does not
have growth defects, but none of these pathways was found to
be affected (Supplementary Table 3). To further corroborate
these results, we silenced CCAR2 in U2OS cells and
evaluated its effect on NF-kB, AKT and ERK1/2 activation.
Compared with the control, CCAR2 silencing (Figure 2b)
determined a reduction in AKT phosphorylation on S473
(a hallmark of its activation), whereas it left unaltered ERK1/2
and NF-kB. On the other hand, CCAR2 depletion in BJ-hTERT
cells induced AKTactivation (Figure 2c).
Altogether these results suggest that CCAR2 loss nega-
tively impacts on AKTactivation only in cancer cells.
CCAR2 specifically regulates the proliferation of human
cancer cell lines. CCAR2 loss was reported to specifically
reduce the growth of cancer cells with mutant p538 and
negatively affect the proliferation of estrogen receptor (ER)
negative cells,17 whereas its role in ER positive cells growth is
disputed.18,19 Therefore, we extended the analysis of CCAR2
silencing effects to a panel of several cancer cell lines with
different p53 and ER status (Supplementary Table 4A and B),
and we intriguingly found that CCAR2 depletion strongly
inhibited the proliferation of lung, osteosarcoma and breast
cancer cells (A549, SAOS2, MCF-7, MDA-MB-231, BT549,
and MDA-MB-453) regardless of p53 and ER status
(Figure 3a; Supplementary Figures 3A and C). Conversely,
as for BJ-hTERT, CCAR2 silencing had no effect on the
growth of non malignant cells (like MCF10A, HME and
IOSE80) (Figure 3b; Supplementary Figures 3B and C). We
next verified the effect of CCAR2 knock-down on AKT
activation and interestingly found a correlation in all cancer
cells between growth inhibition and decreased AKT phos-
phorylation (Figure 4a). On the other hand, the lack of growth
defects in the CCAR2-depleted normal cells was associated
with increased levels of phosphorylated AKT (Figure 4b).
To evaluate the specificity of this phenomenon, we
transfected A549 and HME cells with other two siRNA
sequences or with their combination and we evaluated their
effect on cellular proliferation and AKT phosphorylation. We
found that all the tested siRNAs induce a proliferation defect
associated with reduced AKT phosphorylation in A549, but not
in HME cells (Supplementary Figures 4A and B).
To prove that the proliferation defect caused by CCAR2
depletion depends on reduced AKT activation, U2OS and
A549 cells were silenced for CCAR2 and PTEN, to mimic
constitutive AKT activation, and their effect on cellular
proliferation and AKT phosphorylation was verified. We
demonstrate that PTEN depletion rescued the growth defect
induced by CCAR2 depletion in U2OS and, partially, in A549
cells and restored the phosphorylation of AKT in both cell lines
(Figures 4c and d; Supplementary Figures 5A and B).
Moreover, we silenced AKT and CCAR2 in A549 and HME
cells, and we found that loss of both proteins does not worsen
the anti-proliferative effect of CCAR2 depletion alone in A549,
but reduces the growth of HME cells (Supplementary Figures
6A and B). These data indicate that CCAR2 and AKT have
epistatic roles in cancer cells.
Furthermore, we evaluated if SIRT1, the major CCAR2
target,20 is implicated in this CCAR2 function. As shown in
Supplementary Figure 7, the depletion of SIRT1 did not rescue
the growth defect induced by CCAR2 silencing in A549 cells.
All these data indicate that CCAR2 depletion inhibits
selectively the proliferation of cancer cells, in a SIRT1
independent manner, by reducing AKTactivation.
To better evaluate the biological effect of CCAR2 silencing,
we performed soft agar growth assays with HME and A549
cells. We found that CCAR2 depletion, does not increase the
ability to grow in soft agar of HME cells, despite the induction of
AKT phosphorylation, whereas, as expected, reduces the
anchorage independent growth of A549 cells (Figures 5a
and b). We also tested if CCAR2 overexpression can induce
malignant transformation and found, with a stably transfected
Figure 2 CCAR2 depletion reduces AKT phosphorylation. (a) Pie chart indicating the percentage of up- and downregulated genes identified by the gene expression analysis.
(b) WB analysis of U2OS cells silenced for CCAR2 with the indicated antibodies. (c) WB analysis of control and CCAR2-KO mass culture BJ-hTERT cells with the indicated
antibodies
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clone, that ectopic CCAR2 does not increase the growth in soft
agar of HME cells (Figure 5c). Altogether these results
indicate that alteration of CCAR2 protein levels cannot induce
malignant transformation of normal cells.
Finally, we tested if CCAR2 loss can increase the sensitivity
of cancer cells to anti-cancer agents. For this A549 and HME
cells were silenced for CCAR2 and their viability was analyzed
48 h after etoposide or tamoxifen treatment. As evidenced in
the charts, CCAR2 depletion protected cancer cells from
etoposide induced cell death, but increased their sensitivity to
tamoxifen (Supplementary Figure 8).
CCAR2 depletion affects S-phase progression. To identify
the mechanism responsible for the reduced proliferation of
CCAR2-depleted cancer cells, we initially analyzed the levels
of the apoptotic marker cleaved PARP, but no significant
differences between control and CCAR2-depleted cells were
found except for A549, where a slight increase of cleaved
PARP levels was detectable in CCAR2 silenced cells
(Figure 6a). Moreover, we evaluated the percentage of dead
cells by trypan blue exclusion test in HME, U2OS and A549
cells depleted of CCAR2 and also in this case we confirmed
that CCAR2 absence does not affect the viability of HME and
U2OS cells, whereas it rises the percentage of dead cells in
A549 from about 5–15% (Figure 6b). As these differences
cannot account for the growth defect detected in cancer cells,
we analyzed the effect of CCAR2 silencing on cell cycle
progression. We labeled A549 cells with the 5-bromo-2′-
deoxyuridine analog EdU, which marks S-phase cells8 and
found that the fraction of EdU-positive cells accounted for
40% in siLUC controls and only about 20% in CCAR2
silenced cells (Figure 6c). Notably, no differences in EdU
positivity were found between siLUC and siCCAR2 in the
normal cell line IOSE80 (Figure 6c).
To further ascribe the defect in G1/S transition to the
reduced AKTactivation, we analyzed in different cell lines the
phosphorylation of GSK3β, whose phosphorylation by AKT is
required to allow G1/S progression.12 In accordance with our
hypothesis, we found that the phosphorylation of GSK3β on
Ser9 is reduced in A549, U2OS and MDA-MB-231 cells
depleted of CCAR2, but induced in silenced HME and IOSE80
normal cells (Figure 6d). Altogether these results suggest that
CCAR2 depletion reduces AKT activation and consequently
GSK3β phosphorylation, finally preventing G1/S transition in
cancer cells.
As these data contrast with those we previously published
about normal cell cycle progression of CCAR2-KO U2OS
clones,5 we analyzed proliferation and AKT phosphorylation in
these cells, but we did not find defects in AKT activation or in
the rate of proliferation (Supplementary Figure 9), probably
Figure 3 CCAR2 depletion decreases cancer cell proliferation but preserves the growth of normal cells. Proliferation rate analyses in the indicated cancer (a) and normal
immortalized (b) cell lines silenced for CCAR2 and siLUC as negative control. *Po0.05, **Po0.01, ***Po0.001
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reflecting the acquired ability of CCAR2-KO clones to counter-
act the absence of CCAR2.
CCAR2 inhibits AKT activation by regulating TRB3
expression. To understand the molecular mechanism
underlying CCAR2-dependent regulation of AKT activation,
we performed co-immunoprecipitation analyses in both A549
and MCF10A cells, but we were unable to find any CCAR2-
AKT association (Supplementary Figure 10).
Thus, since our gene expression profile analysis revealed
that in U2OS CCAR2 altered the expression of genes related
to the AKT pathway, we performed RT-qPCR analysis in
different cell lines silenced for CCAR2, with a focus on TRB3,
since alteration in its expression is known to impact on AKT
phosphorylation and activation.14,15 We found that CCAR2
depletion induces the accumulation of TRB3 mRNA and
protein in U2OS and A549 cells, but not in the normal
cell lines HME and IOSE80 (Figures 7a and b). As TRB3
is known to bind and inhibit AKT,14,15 we performed
co-immunoprecipitation analyses in control and CCAR2
silenced cells, and we found that the association between
AKTand TRB3 increases upon CCAR2 depletion in A549 and
U2OS cells (Figures 7c and d), but is not modulated in HME
and IOSE80 cells (Supplementary Figures 11A and B).
Collectively these results indicate that, in cancer cells,
CCAR2 loss induces the accumulation of TRB3 leading to an
augmented binding and inhibition of AKT.
Discussion
Our studies demonstrate a critical role for CCAR2 in cancer
cell proliferation, where its depletion negatively impacts on
their growth ability, but they also interestingly show, for the first
time, that CCAR2 absence preserves the proliferation of
normal cells. This phenomenon suggests that cancer cells,
owing to accumulated alterations during the transformation
process, may become addicted to CCAR2 expression, and its
ablation may establish a synthetic lethality effect.
To understand this phenomenon, we performed gene
expression profiles and found, specifically in CCAR2-
deficient cancer cells, a severe perturbation of the AKT
pathway, which is frequently hyperactivated in several human
tumors and in cancer cell lines.21 Accordingly, we discovered
that CCAR2 depletion determines growth reduction and
impairment of AKT activation in all the tested cancer cells,
even if to a different extent because of the diverse growth rate
of the analyzed cell lines. This growth defect finally results in a
reduced ability to grow in soft agar and increased sensitivity to
tamoxifen treatment, but not to etoposide, which is known to
induce CCAR2-SIRT1 association and apoptosis inhibition.3
By contrast, in non malignant cells, CCAR2 silencing had no
effect on proliferation and was associated with increased AKT
phosphorylation that, however, does not contribute to malig-
nant transformation as both CCAR2 depletion and over-
expression does not allow the anchorage independent growth
Figure 4 CCAR2 depletion reduces AKTactivation in cancer cells, but increases phosphorylated AKT in normal cells. WB analyses of AKT phosphorylation in the indicated
cancer (a) and normal immortalized (b) cell lines silenced for CCAR2. (c) Cell proliferation rate in U2OS cells silenced for CCAR2, PTEN or both CCAR2 and PTEN. ***Po0.001
(d) WB analysis with the indicated antibodies of U2OS cells transfected with siRNA against CCAR2, PTEN and both siCCAR2 and siPTEN
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of normal cells. Thus, it is possible that cells require AKT
activation to survive CCAR2 loss and that only cells with an
intact AKT pathway can do it. However, further experiments
are necessary to determine the reason why CCAR2 has this
effect specifically in cancer cells and not in normal cells. One
hypothesis is that CCAR2 depletion could lead to a synthetic
lethal effect with the hyperactivation of AKT, mainly detectable
in cancer cells. Alternatively, CCAR2 could interact with some
Figure 5 CCAR2 protein levels do not affect malignant transformation. Representative images of colonies formed in soft agar by HME (a) and A549 (b) cells silenced for
CCAR2. (c) Representative images of HME colonies formed in soft agar by a clone stably expressing FLAG-CCAR2
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transcriptional regulators and modulate their activity
differently in cancer and normal cells. Accordingly, the
expression of genes implicated in the induction of AKT
function, such as MSR1 and RAB11-FIP1,22,23 has been
found deregulated in BJ-hTERT cells and, on the contrary,
genes involved in AKT repression are specifically
altered in U2OS cells. Another possibility is that CCAR2 loss,
which is known to induce metabolic defects,24 could be more
detrimental in cancer than in normal cells because of the
Warburg effect and because of normal cells ability to activate
AKT also in the absence of CCAR2. In accordance with this
hypothesis, we found that TRB3, whose gene transcription is
induced by aminoacids deprivation,25 and which is known to
inhibit AKT activation,15,16 is upregulated in cancer cells
depleted of CCAR2, but not in normal cells. Therefore, we
demonstrated that the inhibition of AKT activity by
CCAR2 depletion in cancer cells could be, at least in part,
due to the upregulation of TRB3 gene, which results in
TRB3 protein accumulation and increased interaction
with the AKT protein. Differently, the inability to induce TRB3
accumulation, could explain the reason why in normal
cells CCAR2 depletion can promote AKT phosphorylation.
Unfortunately, we were not able to perform proliferation
assays in cells silenced for CCAR2 and TRB3, because of
the reported toxic effect of TRB3 depletion.26,27 Anyway, other
genes encoding for proteins related to the AKT pathway
could also be implicated as suggested by our results and
previous reports. Indeed, we found that in CCAR2-depleted
cells also the expression of IGFBP5, PPARG and
PDGFA is altered and all these proteins can directly or
indirectly regulate AKT activation.16,28–30 Moreover, it was
previously shown that CCAR2 regulates breast and
colon cancer progression by acting respectively as PEA3
and PROX-1 transcription factors co-activator7,17 and, of note
also these proteins are implicated in AKT pathway
regulation.31,32
Figure 6 CCAR2 depletion prevents G1/S-phase transition in cancer cell lines. Normal and cancer cells silenced for CCAR2 were analyzed by western blot for the levels of
cleaved PARP protein (a) and by trypan blue exclusion test for the percentage of dead cells (b). (c) A549 and IOSE80 cells transfected with siCCAR2 and siLUC were incubated in
EdU containing medium for 1 h 30 min. EdU-positive cells were stained, enumerated and data reported in the chart (top). **Po0.01 WB analysis of A459 and IOSE80 cells
transfected with siCCAR2 and siLUC, with the indicated antibodies (bottom). (d) WB analysis of cancer (U2OS and A549) and normal immortalized cells (HME and IOSE80)
silenced for CCAR2 with the indicated antibodies
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Finally, our studies suggest a model (Figure 7e) in which
CCAR2 depletion in cancer cells promotes the inactivation of
the AKT pathway by altering the transcription of genes coding
for proteins implicated in the regulation of AKTactivity, such as
TRB3. AKT inactivation then leads to reduced phosphoryla-
tion of GSK3β, which in turn prevents G1/S-phase progression
and cells proliferation. In normal cells, however, CCAR2
depletion leads to AKT activation and leaves unaltered the
Figure 7 CCAR2 depletion induces the expression of TRB3 in cancer cell lines. (a) Expression of TRB3 was analyzed by RT-qPCR in cancer (U2OS and A549) and normal
cells (HME and IOSE80) transfected with siCCAR2 and siLUC. *Po0.05, **Po0.01. (b) WB analyses of cancer and normal immortalized cells transfected with siCCAR2 and
siLUC with the indicated antibodies. AKT immunoprecipitates from A549 (c) and U2OS (d) cells silenced for CCAR2 and LUC were analyzed byWB with the indicated antibodies.
PC= negative control. (e) Graphical representation of our working model
CCAR2-dependent regulation of cancer cell growth
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cellular growth. However, further studies will be necessary to
elucidate the mechanisms responsible for this differential
behavior of CCAR2 in normal and cancer cells and will provide
useful insights for the discovery of novel therapeutic targets for
the treatment of multiple cancers.
Materials and Methods
Cell lines. Human osteosarcoma U2OS and SAOS cells, human lung cancer
A549 cells, breast cancer MCF-7, BT549 and MDA-MB-453 cells were grown in
DMEM (Lonza, Basel, Switzerland) with 10% of fetal bovine serum (FBS). Breast
cancer MDA-MB-231 and the normal ovarian IOSE80 cells were cultured in
RPMI-1640 (Lonza) with 10% FBS. BJ-hTERT human fibroblast cells were grown in
DMEM/Medium199 (4:1) with 10% of fetal bovine serum and 10 μg/ml Hygromycin
B. Human non tumorigenic mammary epithelial MCF10A and HME cells were
cultured in DMEM/F12 (1:1, Lonza) with 10% of FBS, insulin (5 μg/ml),
hydrocortisone (1 μg/ml), and human epidermal growth factor (hEGF; 10 ng/ml).
Expression vectors, siRNAs and transfections. siRNAs against
CCAR2 were iBONi siRNA Pool (RIBOXX, Radebeul, Germany) or single
sequences. siRNA against SIRT1 were ON-TARGET plus SMART pool (GE
Healthcare Dharmacon, Lafayette, CO, USA), whereas those against PTEN and
AKT were FlexiTube siRNA (Qiagen, Valencia, CA, USA). Lipofectamine 2000
(Thermo Fisher Scientific, Waltham, MA, USA) and Lipofectamine RNAiMAX
(Thermo Fisher Scientific) were used for plasmids and siRNAs transfections,
respectively, according to the manufacturer’s instructions.
Cell growth analysis. The day after control or CCAR2 siRNA transfection,
cells were seeded in a 12 wells plate at 10 000 cells per well (for MCF10A 20000
cells were seeded) in duplicate. Grown cells were then counted at the indicated
days and results of three independent experiments were reported in the chart.
To test the sensitivity to anti-cancer agents, cells transfected with CCAR2 siRNA
were seeded in a 96 wells plate and, 24 h later, treated with etoposide or tamoxifen at
the indicated concentrations. Viability was determined 48 h after treatment by
CellTiter-Glo Cell Viability Luminescent Assay (Promega, Madison, WI, USA)
according to manufacturer’s procedures.
Soft agar assay. Soft agar assays were performed as previously described.33
Briefly, 5 × 104 cells were suspended in 1.5 ml of the appropriate complete medium
containing 0.33% agar, added into a layer of complete medium containing 0.5%
agar and incubated for 3 weeks. Plates were then analyzed for colony number and
size and representative images were captured by optical microscope.
Western blot, antibodies and immunoprecipitations. The NuPAGE
system (Thermo Fisher Scientific) was used for western blot analyses.4
Quantification of protein levels were normalized to loading control and for
phosphorylated proteins to total proteins. Proteins were transferred to a PVDF
membrane (Protran, Merck Millipore, Darmstadt, Germany). The blots were
incubated with the following antibodies: CCAR2 (Bethyl Laboratories, Montgomery,
TX, USA or Cell Signaling Technology, Danvers, MA, USA); phospho-AKT-S473
(Cell Signaling Technology), pan-AKT (Cell Signaling Technology), SIRT1 (Cell
Signaling Technology), PTEN (Cell signaling Technology), Vinculin (Sigma-Aldrich,
Darmstadt, Germany) and β-Actin (Sigma). For immunoprecipitation analyses, A549
and MCF10A cells were lysed with ELB buffer3 and 1 mg of total protein extracts
were incubated with anti-CCAR2 antibody (Bethyl Laboratories) for 4 h at 4 °C.
Beads were washed three times with ELB buffer and then resuspended in Laemmli
buffer heated at 98 °C, loaded on NuPAGE gels and subjected to western blot
analyses with the indicated antibodies.
Microarray analyses. Total RNA was isolated from U2OS and BJ-hTERT
samples using Qiazol (Qiagen, Valencia, CA, USA) reagent. After a clean-up
treatment with RNAeasy kit following the manufacture’s recommendations (Qiagen)
and with RNase-free DNase to remove contaminating genomic DNA, RNA integrity
and purity was assessed by Bioanalyzer (Agilent Technology, Santa Clara, CA,
USA).
RNA samples were processed for microarray hybridization by the Functional
Genomics core facility at the Fondazione INT (Milan). Briefly, 300 ng of total RNAwas
reverse transcribed, labeled with biotin and amplified overnight (14 h) using the
Illumina RNATotalPrep Amplification kit (Ambion, Thermo Fisher Scientific, Waltham,
MA, USA) according to manufacturer’s protocol. Overall, 1 µg of the biotinylated
cRNA sample were mixed with the Hyb E1 hybridizatioin buffer containing 37.5% (w/
w) formamide and then hybridized to Sentrix Bead Chip Human HT12_v4 (Illumina,
San Diego, CA, USA) at 58 °C overnight (18 h). The array represents over 47 000
bead types, each with a unique sequence derived from human genes in the National
Centre for Biotechnology Information Reference Sequence and UniGene database.
Array chips were washed with manufacturer’s E1BC solution, stained with 1 µg/ml
Cy3-streptavidine (Amersham Biosciences) and eventually scanned with Illumina
BeadArray Reader. We collected primary data using the supplied scanner software
and GenomeStudio v2009.1 software package (Illumina, San Diego, CA, USA).
Microarray data were analyzed through the R programming language (v 3.0.0,
http://www.R-project.org/). All samples passed quality controls; raw data were log2
transformed and normalized using the robust spline normalization (RSN) method
implemented in the lumi34 package of Bioconductor.35 Probes with a detection
P-valueo0.01 in at least 1 sample were included in the statistical analysis; in case of
multiple probes targeting the same gene symbol, the probe detected in the highest
number of samples was selected (the probe with the highest interquartile range was
chosen in case of equal detection rate). The class comparison analysis was
performed using a moderated t-test as implemented in the limma package.36 P-values
were adjusted for multiple testing using Benjamini–Hochberg false discovery rate
(FDR). The genes with an absolute fold change⩾ 2 and FDR⩽ 0.01 were considered
statistically significant. To evaluate the fine-tuning gene deregulation in response to
the CCAR2 inactivation a less stringent analysis was performed (FC⩾ 1.5 and
FDR⩽ 0.05) and the differentially expressed genes were loaded in the Ingenuity
Pathway Analysis software (www.ingenuity.com) to point out the deregulated gene
networks. Microarray data were deposited and are available on NCBI Gene
Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/) with the
accession number GSE87364.
RNA extraction and real-time quantitative PCR. For quantitative real-
time quantitative PCR (qPCR) total RNA was extracted from U2OS, A549, HME and
IOSE80 cells with the mRNeasy mini columns. Overall, 1 μg of total RNA was
reverse transcribed using the Transcriptor First Strand c-DNA Synthesis kit (Roche,
Basel, Switzerland). real-time qPCR was performed with SYBR Green qPCR
Master Mix (Thermo Fisher Scientific) and GAPDH mRNA was used for
normalization. Primers used were: TRB3_forward TGCCCTACAGGCACTGAGTA;
TRB3_reverse GTCCGAGTGAAAAAGGCGTA; GAPDH_forward AATCCCATCA
CCATCTTCCA and GAPDH_reverse TGGACTCCACGACGTACTCA.
Evaluation of G1/S transition. DNA replicating cells were evaluated with
the Click-iT EdU assay kit (Thermo Fisher Scientific) as previously described.37
Briefly, cells were cultured in EdU containing medium for 1 h and 30 min and then
stained according to manufacturer’s instructions. Cells positive for EdU were
counted and expressed as percentage of the total population.
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